Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 16/20 | 0.81 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29352194 | 0.93 | CETP (0.81) | CETP | |
| SCHEMBL529503 | 0.93 | CETP (0.81) | CETP | |
| SCHEMBL14273089 | 0.92 | CETP (0.76) | CETPMME | |
| SCHEMBL14643008 | 0.92 | CETP (0.79) | CETPMME | |
| SCHEMBL18011036 | 0.91 | CETP (0.78) | CETPMME | |
| SCHEMBL2701570 | 0.91 | CETP (0.78) | CETPMME | |
| SCHEMBL2703171 | 0.90 | CETP (0.77) | CETPMME | |
| SCHEMBL528587 | 0.90 | CETP (1.00) | CETPMME | |
| SCHEMBL23977331 | 0.89 | CETP (0.74) | CETPMME | |
| SCHEMBL16844336 | 0.89 | CETP (0.82) | CETPMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190224147-A1 | CETP MODULATOR FOR USE IN THE TREATEMENT OF EYE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2019-07-25 | — | — | US | disclosed |
| CN-106559998-A | Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agents | 豪夫迈·罗氏有限公司 | 2017-04-05 | — | — | CN | disclosed |
| US-20160287537-A1 | CETP MODULATOR FOR USE IN THE TREATEMENT OF EYE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2016-10-06 | — | — | US | disclosed |
| EP-2448918-B1 | PREPARATION AND CRYSTALLISATION OF S-[2-[1-(2-ETHYLBUTYL)CYCLOHEXYLCARBONYLAMINO]-PHENYL]-2-METHYLTHIOPROPIONATE | HOFFMANN LA ROCHE (CH) | 2016-08-03 | — | — | EP | disclosed |
| WO-2015091410-A1 | CETP MODULATOR FOR USE IN THE TREATMENT OF EYE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| US-20140243414-A1 | PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS | JAPAN TOBACCO INC. (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20140243414-A1 | PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS | JAPAN TOBACCO INC. (JP) | 2014-08-28 | — | — | US | disclosed |
| US-8765989-B2 | Process | HOFFMANN - LA ROCHE INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140121229-A1 | COMBINATION COMPRISING S-[2-([[1-(2-ETHYLBUTYL)CYCLOHEXYL] CARBONYL]AMINO)PHENYL] 2-METHYLPROPANETHIOATE AND AN HMG COA REDUCTASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2014-05-01 | — | — | US | disclosed |
| US-20140121229-A1 | COMBINATION COMPRISING S-[2-([[1-(2-ETHYLBUTYL)CYCLOHEXYL] CARBONYL]AMINO)PHENYL] 2-METHYLPROPANETHIOATE AND AN HMG COA REDUCTASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2014-05-01 | — | — | US | disclosed |
| US-20130338391-A1 | NOVEL PROCESS | HOFFMANN-LA ROCHE INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-20130079541-A1 | NOVEL PROCESS | HOFFMANN-LA ROCHE INC. (US) | 2013-03-28 | — | — | US | disclosed |
| EP-2448918-A2 | PREPARATION AND CRYSTALLISATION OF S-[2-[1-(2-ETHYLBUTYL)CYCLOHEXYLCARBONYLAMINO]-PHENYL]-2-METHYLTHIOPROPIONATE | F. Hoffmann-La Roche AG (CH) | 2012-05-09 | — | — | EP | disclosed |
| US-20080045599-A1 | Method for Increasing the Bioavailability of the Active Form of S-[2-([[1-(2-Ethylbutyl)Cyclohexyl]Carbonyl] Amino)Phenyl] 2-Methylpropanethioate | JAPAN TOBACCO INC. (JP) | 2008-02-21 | — | — | US | disclosed |
| US-7276536-B2 | Method for increasing the bioavailability of the active form of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino) phenyl] 2-methylpropanethioate | JAPAN TOBACCO INC. (JP) | 2007-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045599-A1 | Method for Increasing the Bioavailability of the Active Form of S-[2-([[1-(2-Ethylbutyl)Cyclohexyl]Carbonyl] Amino)Phenyl] 2-Methylpropanethioate | SLC7A1, SLC10A2, SLCO2B1 | CETP 90/4885MME 1654/4885HSD17B10 1007/4885 |
| US-20140121229-A1 | COMBINATION COMPRISING S-[2-([[1-(2-ETHYLBUTYL)CYCLOHEXYL] CARBONYL]AMINO)PHENYL] 2-METHYLPROPANETHIOATE AND AN HMG COA REDUCTASE INHIBITOR | HMGCR, COASY, PCSK9 | CETP 8/4885MME 2094/4885HSD17B10 33/4885 |
| US-20130079541-A1 | NOVEL PROCESS | CYP3A4, CYP4B1, CYP11B2 | CETP 448/4885MME 579/4885HSD17B10 566/4885 |
| US-20160287537-A1 | CETP MODULATOR FOR USE IN THE TREATEMENT OF EYE DISEASE | CETP, MTTP, APOB | CETP 1/4885MME 568/4885HSD17B10 1255/4885 |
| US-20130338391-A1 | NOVEL PROCESS | CYP3A4, CYP4B1, CYP11B2 | CETP 448/4885MME 579/4885HSD17B10 566/4885 |
| US-20140243414-A1 | PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS | CETP, NPC1L1, LCAT | CETP 1/4885MME 527/4885HSD17B10 245/4885 |
| US-20190224147-A1 | CETP MODULATOR FOR USE IN THE TREATEMENT OF EYE DISEASE | CETP, MTTP, APOB | CETP 1/4885MME 441/4885HSD17B10 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.